Sebastien Noel from Veeva Systems considers the potential benefits and drawbacks of messaging services for HCPs as well as explaining Veeva’s own platform, which combats these issues

Alex Devereson and Delphine Zurkiya from McKinsey consider the value of generative AI in the pharma industry

Frances Ramsay from InnoScot Health discusses the way forward in closing the gender health gap

Dr Charlotte Owens from Organon explores the impact of innovations in contraception and how this can reduce unintended pregnancy rates

Professor Tobias Arkenau from Ellipses Pharma explores the need and potential for next generation treatments as well as the global need to keep improving the clinical trial structure and landscape

Dr Gen Li, president at Phesi, considers patient enrolment and retention in clinical trials, with a focus on oncology trials and the challenges facing them

Santosh Sahu at Charac considers the NHS’ Pharmacy First scheme, it benefits and the barriers to its implementation

Pharmafocus speaks to Gilead Sciences about the current treatments available for blood cancers and how they are likely to develop in the future

Emma Bishop at Cognitant Group explores the need for patient support programmes, and how these can be improved

Lykke Pedersen from Abzu considers the benefits of AI and its different applications within the pharma industry

Paul Reed and Annabelle Gall at Research Partnership, an Inizio Advisory company, consider the benefits and drawbacks of AI, especially in terms of diversity and synthetic patients

Soraya Bekkali from Alexion, AstraZeneca Rare Disease, explains why the EU must act in 2024 to tackle the health equity crisis that people living with rare diseases face every day